Tag Archives: Cardinal Health

DEA bans Walgreens from shipping Oxy in Fla.

The U.S. Drug Enforcement Agency has barred Walgreens from shipping oxycodone and other controlled drugs from its Jupiter, Fla., distribution center after finding that the company failed to maintain proper controls to ensure it didn’t dispense drugs to addicts and drug dealers.

According to the DEA, the distribution center has been the single largest distributor of oxycodone products in Florida since 2009. In 2011, 16 of the top 25 largest oxycodone purchasers by Walgreens retail pharmacies, including the top six purchasers, were in Florida and supplied by the Jupiter center, the agency said.

The strike against Walgreens comes just after the DEA revoked the controlled substances licenses for two CVS pharmacies in Sanford, Fla., after also accusing them of dispensing excessive amounts of oxycodone.

Separately in May, Cardinal Health reached a deal with the DEA that blocked its Lakeland, Fla. facility from distributing controlled substances for two years following similar accusations.

Posted in Informational, Pharmaceutical Industry, Policy & Regulation | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Cardinal settles with DEA over painkiller distribution

Cardinal Health has reached a deal with the Drug Enforcement Administration that will block one of its Florida facilities from distributing controlled substances for two years. The company also said it will take steps to improve anti-diversion procedures designed to prevent prescription drugs from being abused.

Earlier this year, the DEA suspended Cardinal’s license after finding that the company – which is one of the nation’s largest distributors of pharmaceuticals – sold excessive amounts of oxycodone to four Florida pharmacies. (The suspension related only to the company’s license to distribute controlled substances from its Lakeland, Fla. facility, which the DEA claims shipped 50 times as much oxycodone to its top four customers than it has shipped to its other Florida retail customers.)

Cardinal challenged the suspension in federal court, and both the company and the DEA filed documents that gave an inside look into how prescription painkillers have flooded the black market.

Cardinal was initially granted a temporary restraining order blocking the suspension after convincing a judge that the move would disrupt drug shipments to more than 2,500 pharmacy customers in Florida, Georgia and South Carolina. The company said it has “robust controls and performs careful due diligence,” noting that in the past four years, it has stopped shipping controlled medicines to more than 350 pharmacies it determined posed an unreasonable risk of diversion, including 160 in Florida alone.

Posted in Crime, Litigation, Pharmaceutical Industry, Policy & Regulation | Tagged , , , , , , , , , , , , | Leave a comment

Cardinal loses round in DEA painkiller distribution fight

A federal judge has ruled that the Drug Enforcement Administration can block Cardinal Health from distributing controlled substances from one of its Florida facilities. Earlier this month, the DEA suspended Cardinal’s license after finding that the company – which is one of the nation’s largest distributors of pharmaceuticals – sold excessive amounts of oxycodone to four Florida pharmacies. (The suspension relates only to the company’s license to distribute controlled substances from its Lakeland, Fla. facility, which the DEA claims shipped 50 times as much oxycodone to its top four customers than it has shipped to its other Florida retail customers.)

Cardinal challenged the suspension in federal court, and both the company and the DEA filed documents that give an inside look into how prescription painkillers have flooded the black market.

Cardinal was granted a temporary restraining order blocking the suspension after convincing a different judge that the move would disrupt drug shipments to more than 2,500 pharmacy customers in Florida, Georgia and South Carolina. The company said it has “robust controls and performs careful due diligence,” noting that in the past four years, it has stopped shipping controlled medicines to more than 350 pharmacies it determined posed an unreasonable risk of diversion, including 160 in Florida alone.

Posted in Crime, Informational, Pharmaceutical Industry, Policy & Regulation | Tagged , , , , , , , , , , , , , , , | Leave a comment